Hunter Syndrome / MPS II - FDA Rare Disease Listening Session
Thank you for your interest in FDA's Rare Disease Patient Listening Session!
A Listening Session teleconference will be co-hosted by FDA's Patient Affairs Staff and the National Organization for Rare Disorders (NORD) during which the patients or caregivers of patients affected by Hunter Syndrome (mucopolysaccharidosis II or MPS II) will have an opportunity to share first-hand with FDA staff their experiences of living with this disease. The teleconference will be held on Tuesday, February 4, 2020 from 1:30 - 3:00 pm Eastern Time. There are a very limited number of openings for participating in the session, therefore participants will be accepted on a first-come-first-serve basis assuming the participant meets the specific requirements. Those who are selected will be notified by NORD or FDA.